Revolution Medicines RVMD 深 沪
已收盘 10-31 16:00:00 美东时间
58.84
-0.030
-0.05%
华盛通- 最 高59.74
- 今 开58.96
- 成交量 237.83万股
- 最 低 58.28
- 昨 收 58.87
- 总市值 98.29亿
- 52周最高 62.40
- 市盈率 静 --
- 换手率 1.42%
- 52周最低 29.17
- 委 比 98.81%
- 总股本 1.67亿
- 历史最高 62.40
- 量 比 1.05
- 振 幅 2.48%
- 历史最低 14.08
- 每 手 1
- 风险率 6.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多嘉实标普生物科技ETF（QDII）三季报解读：净值增长19.51% 净申购4900万份
主要财务指标：本期利润2.52亿元 期末净值15.23亿元 报告期内（2025年7月1日-9月30日），基金主要财务指标表现如下：本期已实现收益5379.2...
10-28 00:03
易方达标普生物科技LOF三季报解读：C类份额激增309.9% 净值增长率18.38%
主要财务指标：AC类利润双增长 期末净值A类1.4368元 报告期内，易方达标普生物科技指数（QDII-LOF）A类和C类份额均实现盈利，期末净值保持稳定。...
10-27 22:43
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
Revolution Medicines announced that the FDA has granted Orphan Drug Designation to daraxonrasib for treating pancreatic cancer. Daraxonrasib is a RAS(ON) multi-selective inhibitor currently in a global Phase 3 trial for second-line metastatic PDAC. The company plans additional Phase 3 trials for first-line and adjuvant treatments. Pancreatic cancer, highly RAS-addicted, has limited therapy options. Orphan Drug status offers incentives like tax cr...
10-27 12:00
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
Revolution Medicines announced updated clinical data for elironrasib, a RAS(ON) G12C-selective inhibitor, in treating KRAS G12C non-small cell lung cancer patients who previously received KRAS(OFF) inhibitors. Results from a Phase 1 trial showed a 42% confirmed objective response rate and 79% disease control rate. Elironrasib demonstrated durable responses and acceptable tolerability, highlighting potential advancements in RAS-targeted therapies....
10-22 16:12
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
美股收盘：区域银行信贷恐慌退潮，贸易紧张局势缓和，三大指数集体收涨
区域银行信贷恐慌退潮，贸易紧张局势缓和，三大指数集体收涨；特斯拉收涨2.46%，苹果涨1.96%；甲骨文大跌近7%，创1月份以来最大单日跌幅>>
10-18 09:25
'No Need To Sell' Martin Marietta Materials, Cramer Says: 'It's Just A Great Long-Term Hold'
Wells Fargo's Timna Tanners initiated coverage on Martin Marietta Materials with an Equal-Weight rating and announced a price target of $620.
10-17 19:46
Achieve, Disc, Revolution among winners of initial FDA national priority vouchers
Achieve Life Sciences (NASDAQ:ACHV), Disc Medicine (NASDAQ:IRON), and Revolution Medicines (NASDAQ:RVMD) have been selected among the first nine recipients of the FDA Commissioner’s National Priority ...
10-17 19:12
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
